Marcus H. Snow, MD, Assistant Professor of Rheumatology, University of Nebraska, discusses the use of biosimilar treatments in children.
Transcript:
Are there special considerations when using biosimilars in children?
Generally, no. Ultimately, in the pediatric realm, we end up having a lot of extrapolation of data and the biosimilars with the pediatric population should not be; ideally, this would be studied as much as it is in the adult world, but we just do not have that as often.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.